Vigabatrin retinal toxicity in children with Infantile Spasms: an observational cohort study.

C. A. Westall PhD, T. Wright PhD, F. Cortese PhD, A. Kumarappah MSc, O. C. Snead III, MD, FAAN, J. R. Buncie MD, FRCSP.

Supplemental Data
Figure e-1. Survival curves showing the proportion of children without VGB-RD according to sex of the child and duration of drug treatment.

(A) The Kaplan-Meier survival function for girls is depicted by the sold line and that for boys is the grey line. 

(B) The sold line represents the Kaplan-Meier survival function for children who started VGB treatment over the age of 12 months. The grey line represents Kaplan-Meier survival function for children who were younger than 12 months when starting VGB.

mts = months. The small vertical tick-marks represent withdrawal from the study resulting in censoring of this participant from the sample.
Figure e-2. Individual data points of LA 2.29 flicker amplitude, during and after VGB treatment grouped according to VGB-RD status.

(A) Individuals without VGB-RD during VGB treatment,
(B) Individuals with VGB-RD during VGB treatment,
(C) Individuals without VGB-RD following drug treatment.
(D) Individuals with VGB-RD following drug treatment.